Abstract The National Clinical Trials Network (NCTN) Biospecimen Banks receive, process, store, and distribute various types of human biospecimens collected on NCTN clinical trials. The NCTN Biospecimen Banks serve as a critical resource for the cancer research community by providing researchers with quality, clinically annotated biospecimens, ultimately supporting a variety of translational research efforts. Biospecimen access is open to qualified investigators across the entire research community, not just NCTN members, providing opportunities for secondary use in hypothesis-driven studies. Transparent access to these resources is facilitated through the NCTN Catalog and NCTN Navigator, which include publicly available biospecimen inventories. Investigators can explore available biospecimens and submit requests that are subsequently reviewed for scientific merit by the National Cancer Institute (NCI). The NCTN Biospecimen Banks are a unique resource that enables the use of diverse, clinically annotated biospecimens to support research addressing cancer health disparities, precision oncology, and other translational research efforts that will ultimately improve cancer prevention, treatment, and outcomes. Citation Format: Heather A. Lankes, Mark A. Watson, Jeffry P. Simko, Nilsa C. Ramirez, Scott D. Jewell, Lois E. Shepherd, Sumana Dey, Hala R. Makhlouf. The NCTN biospecimen banks resource abstract. In: Proceedings of the 18th AACR Conference on the Science of Cancer Health Disparities; 2025 Sep 18-21; Baltimore, MD. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2025;34(9 Suppl):Abstract nr IA012.
Lankes et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: